Mozart Therapeutics today announced the presentation of preclinical pharmacologic and tolerability data for MTX-101, a bispecific autoimmune checkpoint inhibitor, at the Annual Meeting of the Federation of Clinical Immunology Societies.
SEATTLE, June 21, 2023 /PRNewswire/ -- Mozart Therapeutics, a leading developer of CD8 Treg Modulators for the treatment of autoimmune and inflammatory disease, today announced the presentation of preclinical pharmacologic and tolerability data for MTX-101, a bispecific autoimmune checkpoint inhibitor, at the Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS 2023). Presented findings include:
The poster “Pre-clinical Pharmacologic and Tolerability Characterization of MTX-101, a Novel KIR x CD8 Targeting Bispecific CD8 Treg Modulator” (Abstract #1517124) can be accessed from the Mozart Therapeutics website. About MTX-101 MTX-101 is a bispecific CD8 Treg Modulator targeting inhibitory KIR and CD8 expressed on regulatory CD8 T cells. This autoimmune checkpoint inhibitor aims to restore regulatory CD8 T cell function, acting early in the autoimmune disease process to halt downstream inflammation and prevent further complication. The initial therapeutic focus for MTX-101 is gastro-intestinal autoimmune disorders. About Mozart Therapeutics Mozart Therapeutics is focused on developing disease-modifying therapies for autoimmune and inflammatory diseases that work by targeting a novel regulatory CD8 T regulatory cell network. The company is headquartered in Seattle, WA. For more information visit www.mozart-tx.com and follow the company on LinkedIn @Mozart-tx. View original content to download multimedia:https://www.prnewswire.com/news-releases/mozart-therapeutics-presents-preclinical-data-for-mtx-101-a-novel-cd8-treg-network-modulator-for-treatment-of-autoimmune-disease-at-focis-2023-annual-meeting-301856220.html SOURCE Mozart Therapeutics |